Monopar Therapeutics Form 4 insider transactions

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reported the acquisition of common stock in multiple transactions between June 13 and June 17, 2024.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, recently purchased 24,000 shares of the company's common stock.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, has recently acquired a total of 36,000 shares of common stock through a series of transactions.

Chandler Robinson, CEO of Monopar Therapeutics, exercised stock options to acquire 84,000 shares of common stock.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports acquisition of stock options.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units related to vesting.

Kim R. Tsuchimoto, CFO of Monopar Therapeutics, reports the vesting and settlement of restricted stock units resulting in the acquisition and disposal of common stock.

Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units related to vesting.